SMTL ID : 5opb.1

Structure of CHK1 10-pt. mutant complex with indazole LRRK2 inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.55 Å

Oligo State

monomer

Ligands

1 x A1N: (2~{R},6~{S})-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1~{H}-indazol-3-yl]pyrimidin-4-yl]morpholine(Non-covalent)

A1N.1: 15 residues within 4Å: Chain A: L.15, E.17, G.18, V.23, A.36, M.84, E.85, L.86, A.87, S.88, G.90, H.134, N.135, L.137, A.147 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:L.15, A:V.23, A:V.23, A:A.36, A:M.84, A:L.86, A:L.137, A:A.147 Hydrogen bonds: A:E.85, A:A.87 Water bridges: A:S.91

2 x CL: CHLORIDE ION(Non-functional Binders)

CL.2: 2 residues within 4Å: Chain A: Y.157, N.158 Ligand excluded by PLIP CL.3: 1 residues within 4Å: Chain A: A.200 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Williamson, D.S. et al., Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). J. Med. Chem. (2017)

Release Date

2017-10-25

Peptides

Serine/threonine-protein kinase Chk1: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Serine/threonine-protein kinase Chk1

Related Entries With Identical Sequence